Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
about
Molecular basis of reduced glucosylceramidase activity in the most common Gaucher disease mutant, N370SCyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analoguesBinding of 3,4,5,6-Tetrahydroxyazepanes to the Acid-β-glucosidase Active Site: Implications for Pharmacological Chaperone Design for Gaucher DiseaseBicyclic (galacto)nojirimycin analogues as glycosidase inhibitors: effect of structural modifications in their pharmacological chaperone potential towards β-glucocerebrosidase.Selection of the biological activity of DNJ neoglycoconjugates through click length variation of the side chain.Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds.Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis.Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.Synthesis and evaluation of [(11)C]PBD150, a radiolabeled glutaminyl cyclase inhibitor for the potential detection of Alzheimer's disease prior to amyloid β aggregation.pH-Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases.Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study.Pharmacological small molecules for the treatment of lysosomal storage disorders.Pharmacological chaperone therapy for Gaucher disease: a patent review.Glucocerebrosidase inhibitors for the treatment of Gaucher disease.sp2-Iminosugar O-, S-, and N-glycosides as conformational mimics of α-linked disaccharides; implications for glycosidase inhibition.Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia.Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.Small molecules as therapeutic agents for inborn errors of metabolism.Bicyclic derivatives of L-idonojirimycin as pharmacological chaperones for neuronopathic forms of Gaucher disease.1-Deoxy-D-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines.Structural basis of pharmacological chaperoning for human β-galactosidase.Synthesis of lipophilic 1-deoxygalactonojirimycin derivatives as D-galactosidase inhibitors.A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis.New insights into the pharmacological chaperone activity of c2-substituted glucoimidazoles for the treatment of Gaucher disease.Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier.Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.
P2860
Q24621867-7A77E2CC-390A-4D68-8939-03366AEE0539Q27667205-7F96376E-7C5D-4D6D-9244-1D80BD0D2819Q27675348-AC320D2D-9CCF-42C7-8D0B-ECCA68CD39CEQ33858358-362D4A58-1927-4360-897B-777AC43FC114Q33879577-62ECDF96-9792-4B5C-80D2-E5876EBB8479Q34464236-EEAC28A4-DE2F-4686-8C03-E1C0FA423514Q34985010-5B31D30B-6706-4D05-A829-00EB344BB75EQ35007910-04BEDFA3-FCD1-41D6-A547-0B9BD8219B90Q35760380-CE5ACA43-E38A-4FB5-8CDD-101A64EC54E9Q35781202-7D0649A4-C739-49BF-81DF-68A612FE2AECQ36639634-53F7638E-A7DA-46BA-BBEB-D11585A4A7E8Q37799818-725F4F3D-B7B8-4CED-AE6C-76B86267E4D2Q37860332-EBB12372-1E6C-404F-80CC-A521530A3A45Q38097869-68CACEF4-E828-4D58-A0D1-A84B7602A1F0Q38324679-E886C09F-45C3-4A85-AE53-0269A0696655Q38670410-7F7CF116-BF9B-4240-858A-4D729BBD63B9Q38797648-523A766C-AE14-4FE7-8C82-0B969474C393Q39038060-9F40C90A-F5C7-4D06-A623-61BF02EEC21CQ39162679-0A38EDBD-B36A-45ED-9D3D-8F43F17A8A20Q39529765-E8BC9061-71C5-4216-8EFF-40CE8923B676Q39885525-E9D7D722-0D19-4867-91C9-1CAB9505D441Q40683720-06F11BF2-E42E-4698-9436-60DEFA41F819Q41574484-FC564E89-C095-48D7-87C4-5EC09BC98B16Q45931929-EDA98A20-DBAD-416F-8B25-86020D2D0A9BQ51750678-6DBFDC66-169B-4E62-9BBD-1B1C0771BCA0Q54945677-10553BB6-E09A-49A1-BC56-C38F795DA233
P2860
Chaperone activity of bicyclic nojirimycin analogues for Gaucher mutations in comparison with N-(n-nonyl)deoxynojirimycin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Chaperone activity of bicyclic ...... utations in comparison with N-
@nl
Chaperone activity of bicyclic ...... h N-(n-nonyl)deoxynojirimycin.
@en
type
label
Chaperone activity of bicyclic ...... utations in comparison with N-
@nl
Chaperone activity of bicyclic ...... h N-(n-nonyl)deoxynojirimycin.
@en
prefLabel
Chaperone activity of bicyclic ...... utations in comparison with N-
@nl
Chaperone activity of bicyclic ...... h N-(n-nonyl)deoxynojirimycin.
@en
P2093
P356
P1433
P1476
Chaperone activity of bicyclic ...... h N-(n-nonyl)deoxynojirimycin.
@en
P2093
Haruaki Ninomiya
José M García Fernández
Katsumi Higaki
Kousaku Ohno
M Isabel García-Moreno
Matilde Aguilar-Moncayo
Yoshiyuki Suzuki
P304
P356
10.1002/CBIC.200900442
P577
2009-11-01T00:00:00Z